Mark Purcell
Stock Analyst at Morgan Stanley
(0.87)
# 3,990
Out of 5,140 analysts
6
Total ratings
33.33%
Success rate
-7.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Purcell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNY Sanofi | Upgrades: Overweight | $56 → $58 | $46.76 | +24.04% | 2 | Sep 8, 2025 | |
| NVS Novartis AG | Initiates: Equal-Weight | $114 | $162.67 | -29.92% | 1 | Jan 23, 2024 | |
| GSK GSK plc | Initiates: Equal-Weight | $44 | $59.52 | -26.08% | 1 | Jan 23, 2024 | |
| AZN AstraZeneca | Initiates: Overweight | $85 | $204.20 | -58.37% | 1 | Jan 23, 2024 | |
| NVO Novo Nordisk | Initiates: Overweight | $120 | $47.42 | +153.06% | 1 | Jan 23, 2024 |
Sanofi
Sep 8, 2025
Upgrades: Overweight
Price Target: $56 → $58
Current: $46.76
Upside: +24.04%
Novartis AG
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $114
Current: $162.67
Upside: -29.92%
GSK plc
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $44
Current: $59.52
Upside: -26.08%
AstraZeneca
Jan 23, 2024
Initiates: Overweight
Price Target: $85
Current: $204.20
Upside: -58.37%
Novo Nordisk
Jan 23, 2024
Initiates: Overweight
Price Target: $120
Current: $47.42
Upside: +153.06%